Elvina Almuradova on the life-saving role of fusion testing – Oncogenic gene fusions in cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“Excellent Nature Review to bookmark!
“Oncogenic Gene Fusions in Cancer: From Biology to Therapy” (Liu et al., Nature 2025)
This comprehensive review highlights how gene fusions, once considered rare and niche, are now becoming key players in precision oncology.
Why are gene fusions so important?
– They can drive cancer.
– They can predict response to targeted therapy.
– And detecting them can change patient outcomes.
Most frequent actionable fusions:
• ALK, ROS1, NTRK, RET, FGFR, NRG1
Cancers where fusion testing is highly recommended:
• NSCLC
• Prostate Cancer
• Cholangiocarcinoma
• Ovarian Cancer
• Pancreatic Cancer
• Thyroid Cancer
– Tumor-agnostic approvals are increasing.
– Fusion-driven targeted therapies are expanding.
– RNA-based NGS is becoming gold standard.
A must-read for every oncologist, pathologist and researcher working in the era of precision medicine.
Fusion testing saves lives.”
Oncogenic gene fusions in cancer: from biology to therapy
Authors: Stephen V. Liu et al.
More posts featuring Elvina Almuradova on OncoDaily.
Learn more about precision oncology on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023